Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
Pfizer Inc filed a Form 13F reporting institutional holdings, listing 24 reported positions with an aggregate market value of $576,193,012. The filing was signed by Madelyn D. Purcell on 08-11-2025 and indicates no other managers are included.
Pfizer Inc. (PFE) – Form 4 insider filing shows Chairman & CEO Albert Bourla acquired a de minimis 26 phantom stock units on 31-Jul-2025 through the company’s Non-Funded Deferred Compensation and Supplemental Savings Plan (SSP).
• Transaction code: A (acquisition).
• Unit price: $23.29.
• Total value: ≈ $606.
• Post-transaction holdings: 731,620 phantom stock units, held directly (D).
Phantom units are cash-settled and do not alter the public share count; the participant may transfer them into another investment option at any time. No common stock transactions were reported in Table I.
Materiality: The addition represents less than 0.01 % of Bourla’s existing derivative position and has no discernible impact on Pfizer’s capital structure or governance.